Thalia Therapeutics Plc (AIM:THAT)

London · Delayed Price · Currency is GBP · Price in GBX

0.6100

+0.0350 (6.09%)

Sep 25, 2026, 1:07 PM GMT

Market Cap	6.95M +15.1%
Revenue (ttm)	7.26K -0.2%
Net Income	-1.21M
EPS	-0.00
Shares Out	1.21B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,693,570
Open	0.6000
Previous Close	0.5750
Day's Range	0.5500 - 0.6150
52-Week Range	0.4000 - 0.9500
Beta	0.72
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 30, 2026

About Thalia Therapeutics

Thalia Therapeutics Plc, a biotechnology company, develops and delivers RNA-based therapeutics and technologies in oncology and cardiovascular disease in the United Kingdom. The company develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines. It also develops Nuvec, a pipeline of RNA therapeutics; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation in... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1979

Employees 3

Stock Exchange London Stock Exchange AIM

Ticker Symbol THAT

Full Company Profile

Financial Performance

In 2025, Thalia Therapeutics's revenue was 7,264, a decrease of -0.25% compared to the previous year's 7,282. Losses were -1.21 million, 13.8% more than in 2024.

Financial Statements